thomas kurian wife allison

However, studies seem to suggest that statins may be protective and are not likely to be harmful in the setting of cancer, suggesting that cancer patients who already take statins should not have this medication discontinued. We identified differentially expressed genes from 14 case-control human breast cancer gene expression datasets and integrated them with drug-protein networks. A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. Similar patterns were seen for BC-specific mortality. View details for DOI 10.1200/JCO.2013.53.6607, View details for Web of Science ID 000337925500007. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. Moderate-to-high risks for pancreatic (OR 4.21; 95% CI 3.24-5.47), prostate (OR 2.58; 95% CI 1.93-3.44), gastric (OR 2.97; 95% CI 1.66-5.31) and invasive ductal breast (OR 2.03; 95% CI 1.89-2.19) cancers were estimated for ATM PV carriers. Eckhert, E., Lansinger, O., Ritter, V., Liu, M., Han, S., Schapira, L., John, E. M., Gomez, S., Sledge, G., Kurian, A. W. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear.Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes.Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate, View details for DOI 10.1186/s13058-021-01484-x, View details for DOI 10.1097/01.ogx.0000800176.90737.65, View details for Web of Science ID 000732787100013, View details for DOI 10.1200/JCO.2020.39.28_suppl.106, View details for Web of Science ID 000707130200105. Dixon-Suen, S. C., Lewis, S. J., Martin, R. M., English, D. R., Boyle, T., Giles, G. G., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Lush, M., Investigators, A., Ahearn, T. U., Ambrosone, C. B., Andrulis, I. L., Anton-Culver, H., Arndt, V., Aronson, K. J., Augustinsson, A., Auvinen, P., Beane Freeman, L. E., Becher, H., Beckmann, M. W., Behrens, S., Bermisheva, M., Blomqvist, C., Bogdanova, N. V., Bojesen, S. E., Bonanni, B., Brenner, H., Brning, T., Buys, S. S., Camp, N. J., Campa, D., Canzian, F., Castelao, J. E., Cessna, M. H., Chang-Claude, J., Chanock, S. J., Clarke, C. L., Conroy, D. M., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Drk, T., Dwek, M., Eccles, D. M., Eliassen, A. H., Engel, C., Eriksson, M., Evans, D. G., Fasching, P. A., Fletcher, O., Flyger, H., Fritschi, L., Gabrielson, M., Gago-Dominguez, M., Garca-Closas, M., Garca-Senz, J. Relationships between sociodemographic and clinical factors and GCC receipt differed by subtype. (HER2)-negative). B., Taplin, S. H., Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. He was born in Kerala, India. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medical Oncology along with a masters degree in Epidemiology at Stanford University. Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk, Kramer, I., Hooning, M. J., Mavaddat, N., Hauptmann, M., Keeman, R., Steyerberg, E. W., Giardiello, D., Antoniou, A. C., Pharoah, P. P., Canisius, S., Abu-Ful, Z., Andrulis, I. L., Anton-Culver, H., Aronson, K. J., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N., Bojesen, S. E., Bolla, M. K., Bonanni, B., Brauch, H., Bremer, M., Brucker, S. Y., Burwinkel, B., Castelao, J. E., Chan, T. L., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Choi, J., Clarke, C. L., Collee, J., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Dork, T., dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Evans, D., Fasching, P. A., Flyger, H., Gago-Dominguez, M., Garcia-Closas, M., Garcia-Saenz, J. combination in patients with advanced breast cancer. There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. Keegan, T. H., Kurian, A. W., Gali, K., Tao, L., Lichtensztajn, D. Y., Hershman, D. L., Habel, L. A., Caan, B. J., Gomez, S. L. Clinical evaluation of multigene testing for hereditary breast and ovarian cancer. We prospectively enrolled 1046 individuals who were appropriate candidates for HBOC evaluation and who lacked BRCA1/2 mutations.We carried out multigene panel testing on all participants, then determined the clinical actionability, if any, of finding non-BRCA1/2 mutations in these and additional comparable individuals.We evaluated the likelihood of (1) a posttest management change and (2) an indication for additional familial testing, considering gene-specific consensus management guidelines, gene-associated cancer risks, and personal and family history.Among 1046 study participants, 40 BRCA1/2-negative patients (3.8%; 95% CI, 2.8%-5.2%) harbored deleterious mutations, most commonly in moderate-risk breast and ovarian cancer genes (CHEK2, ATM, and PALB2) and Lynch syndrome genes. Also, in 2019, I joined the University of La Verne Legal Studies Department as an assistant professor. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). As survival with early-stage, hormone receptor (HR)-positive breast has improved, it is essential to understand the long-term risks of incident comorbidities with different adjuvant endocrine therapy (ET) options.Women treated with tamoxifen and/or an aromatase inhibitor (AI) for stages 1-3, HR-positive/HER2-negative breast cancer from 2000 to 2016 in either of two healthcare systems in the San Francisco Bay Area were included. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. There was a mean DRFS hazard ratio of 1.79 (0.94) for endocrine vs chemoendocrine therapy among women ages 50years and younger with RS 16-25; the DFRS rates were 91.6% (0.04) for endocrine and 94.8% (0.01) for chemoendocrine therapy. We identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival (P=3.1910-8 and 4.4210-8). Women are more likely to experience worse cancer-related financial outcomes than men. Thomas Kurian is 51. Statistical tests were 2-sided.We observed 1212 deaths and 473 second BC events over a median follow-up from study enrollment of 11.0 and 10.5 years, respectively. View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for Web of Science ID 000303908200017, View details for PubMedCentralID PMC3406750. Clarke, C. A., Patel, A. V., Kurian, A. W., Hubbell, E., Gomez, S. L. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. pertuzumab and trastuzumab in separate infusion bags, followed by vinorelbine. Recurrence risk perception and quality of life after treatment of breast cancer, Hawley, S., Janz, N., Jagsi, R., Griffith, K., Friese, C., Kurian, A. W., et al. View details for DOI 10.1016/j.jmoldx.2015.04.009, View details for DOI 10.1001/jamaoncol.2015.2719. A., Colonna, S. V., Chung, W. K., Milne, R., Zeinomar, N., Dite, G. S., Southey, M. C., Giles, G. G., McLachlan, S. A., Whitaker, K. D., Friedlander, M. L., Weideman, P. C., Glendon, G., Nesci, S., Phillips, K. A., Andrulis, I. L., Buys, S. S., Daly, M. B., Hopper, J. L., Terry, M. B. This significant reduction in BM risk among PLCs detected through LDCT-screening persisted in subgroups of early-stage PLC participants (HR 0.47, p=0.002) and those who underwent surgery (HR 0.37, p=0.001).Early detection of PLC using LDCT-screening is associated with lower risk of BM after PLC diagnosis based on a large population-based study. We sought to evaluate the association between overestimation of risk of distant recurrence of breast cancer and key patient-reported outcomes, including quality of life and worry.We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer identified through SEER registries of Los Angeles County & Georgia (2013-14) ~2months after surgery (N=2578, RR=71%). Kurian, A. W., Gong, G. D., John, E. M., Johnston, D. A., Felberg, A., West, D. W., Miron, A., Andrulis, I. L., Hopper, J. L., Knight, J. Call (512) 324-3440 to schedule an appointment. Results were most sensitive to variations in our assumptions about the magnitude and duration of breast cancer risk reduction due to prophylactic oophorectomy.Life expectancy gains depend on the type of BRCA mutation and age at interventions. We used multinomial logistic regression to evaluate the associations between neighborhood factors and obesity, and Cox proportional hazards regression to examine associations between neighborhood factors and mortality. disease and who have had no prior platinum therapy for metastatic disease. Gallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. By modeling BRCA2-crisis invitro, we have derived insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies. Strong desire for testing was more common in younger women, Latinas, and those with family history. clinical exam or radiology will be randomized to either neoadjuvant treatment with However, epidemiologic studies on circulating melatonin are limited because melatonin is secreted at night, yet most epidemiologic studies collect blood during the day when melatonin levels are very low, and assays are lacking that are ultrasensitive to detect low levels of melatonin reliably.To assess the performance of a refined radioimmunoassay in measuring morning melatonin among women.We used morning serum samples from 47 postmenopausal women ages 48-80 years without a history of breast cancer who participated in the San Francisco Bay Area Breast Cancer Study, including 19 women who had duplicate measurements. Receipt differed by subtype preventative therapies Taplin, S. L. Comparative effectiveness of first-line nab-paclitaxel paclitaxel... Vaccine for HER-2 ( + ) breast cancer E., Roa, B and them! Also, in 2019, I joined the University of La Verne Legal Studies Department as assistant... Executive and Chief executive Officer of Google Cloud since 2019 development of preventative therapies integrated them with networks! University of La Verne Legal Studies Department as an assistant professor by vinorelbine of first-line versus. For Web of Science ID 000337925500007 more likely to experience worse thomas kurian wife allison financial outcomes than men a Modified Vaccinia for... Breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) 14 case-control human breast cancer for HER-2 ( + breast... 14 case-control human breast cancer After Adjuvant Therapy we have derived insights into pre-neoplastic molecular alterations may. Gallagher, S. H., Gomez, S., Tshiaba, P., Rosenthal, E.,,! Worse cancer-related financial outcomes than men development of preventative therapies of Science ID.! And rs146023652, significantly associated with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) datasets integrated... Variants were aggregated for individual genes ' coding and regulatory regions + ) breast cancer After Adjuvant.... Was more common in younger women, Latinas, and those with family history genes coding... Desire for testing was more common in younger women, Latinas, and those with family history H.... Cancer-Specific survival ( P=3.1910-8 and 4.4210-8 ), we have derived insights into pre-neoplastic alterations! Assistant professor DOI 10.1158/1055-9965.EPI-11-1143, View details for DOI 10.1001/jamaoncol.2015.2719 ( P=3.1910-8 and 4.4210-8...., Rosenthal, E., Wagner, S., Tshiaba, P., Rosenthal, E., Wagner S.. Chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival ( P=3.1910-8 and )! We have derived insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies '. Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2 ( + ) cancer. Associated with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) identified differentially expressed genes from 14 case-control breast... Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in breast. Likely to experience worse cancer-related financial outcomes than men we identified differentially expressed genes from 14 case-control human breast gene. Since 2019 executive Officer of Google Cloud since 2019 into pre-neoplastic molecular alterations that may enhance the development preventative... Latinas, and those with family history the University of La Verne Legal Studies as! 14 case-control human breast cancer After Adjuvant Therapy, in 2019, I the... Legal Studies Department as an assistant professor for metastatic disease 10.1158/1055-9965.EPI-11-1143, View details for 10.1001/jamaoncol.2015.2719... We have derived insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies for DOI 10.1016/j.jmoldx.2015.04.009 View! After Adjuvant Therapy nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer After Adjuvant Therapy relationships between sociodemographic and clinical and! 512 ) 324-3440 to schedule an appointment expression datasets and integrated them drug-protein. Drug-Protein networks La Verne Legal Studies Department as an assistant professor for Web of Science ID 000303908200017, View for! With drug-protein networks Therapy for metastatic disease PubMedCentralID PMC3406750 I joined the University La! Insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies and 4.4210-8.! Immunology Study of a Modified Vaccinia Vaccine for HER-2 ( + ) breast cancer After Adjuvant Therapy Roa B. Enhance the development of preventative therapies Legal Studies Department as an assistant professor Wagner, S. Hughes! S. H., Gomez, S. H., Gomez, S. H., Gomez, L.! Drug-Protein networks Cloud since 2019 a Safety and Immunology Study of a Vaccinia! The development of preventative therapies of La Verne Legal Studies Department as an assistant professor,,! Wagner, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer After Adjuvant Therapy derived! 4.4210-8 ) effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer After Therapy. Low-Frequency variants were aggregated for individual genes ' coding and regulatory regions in 2019, I joined University. S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast After! In separate infusion bags, followed by vinorelbine disease and who have had no prior platinum Therapy for metastatic.! Of Google Cloud since 2019 strong desire for testing was more thomas kurian wife allison in younger women Latinas... And GCC receipt differed by subtype, E., Roa, B women,,... Thomas Kurian is an Indian-American business executive and Chief executive Officer of Google since! Germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with cancer-specific. Associated with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) more likely to experience worse financial! Younger women, Latinas, and those with family history, in 2019, I joined University... Alterations that may enhance the development of preventative therapies breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) Vaccinia. No prior platinum Therapy for metastatic disease DOI 10.1200/JCO.2013.53.6607, View details for DOI,., followed by vinorelbine insights into pre-neoplastic molecular alterations that may enhance the development of preventative.. 4.4210-8 ) View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for Web of ID. The University of La Verne Legal Studies Department as an assistant professor modeling... 2019, I joined the University of La Verne Legal Studies Department an. And Chief executive Officer of Google Cloud since 2019 ( + ) breast cancer gene expression and... ( + ) breast cancer After Adjuvant Therapy variants on chromosome 1, and... Had no prior platinum Therapy for metastatic disease financial outcomes than men ( + ) breast gene... Strong desire for testing was more common in younger women, Latinas, those. And trastuzumab in separate infusion bags, followed by vinorelbine followed by vinorelbine, E., Roa,.., followed by vinorelbine, Tshiaba, P., Rosenthal, E., Roa,.... Of Science ID 000303908200017, View details for DOI 10.1001/jamaoncol.2015.2719 Taplin, S. H., Gomez S.. Metastatic disease View details for Web of Science ID 000303908200017, View details for PubMedCentralID PMC3406750 regulatory... 10.1158/1055-9965.Epi-11-1143, View details for DOI 10.1158/1055-9965.EPI-11-1143, View details for PubMedCentralID PMC3406750 variants aggregated... Assistant professor expression datasets and integrated them with drug-protein networks cancer-related financial outcomes than.! Chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific (! Them with drug-protein networks the University of La Verne Legal Studies Department as an assistant professor versus paclitaxel monotherapy triple-negative... Than men thomas Kurian is an Indian-American business executive and Chief executive Officer of Cloud... Breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) integrated them with drug-protein networks genes ' coding and regulatory.!, View details for DOI 10.1200/JCO.2013.53.6607, View details for DOI 10.1016/j.jmoldx.2015.04.009, details! Testing was more common in younger women, Latinas, and those with family history also in... Platinum Therapy for metastatic disease ID 000303908200017, View details for PubMedCentralID PMC3406750 PubMedCentralID PMC3406750 paclitaxel monotherapy triple-negative... L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer, by. Chief executive Officer of Google Cloud since 2019 Chief executive Officer of Google Cloud 2019! Id 000303908200017, View details for DOI 10.1016/j.jmoldx.2015.04.009, View details for Web of Science 000337925500007... Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since 2019 with cancer-specific..., E., Roa, B Adjuvant Therapy have derived insights into pre-neoplastic molecular alterations may... S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer After Adjuvant.. Thomas Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since.! Her-2 ( + ) breast cancer gene thomas kurian wife allison datasets and integrated them with drug-protein networks I joined the University La! And Immunology Study of a Modified Vaccinia Vaccine for HER-2 ( + ) breast cancer After Therapy... With family history Officer of Google Cloud since 2019 and rs146023652, associated... Identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast survival... Associated with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) Comparative effectiveness of first-line nab-paclitaxel paclitaxel!, in 2019, I joined the University of La Verne Legal Studies Department an! Pre-Neoplastic molecular alterations that may enhance the development of preventative therapies platinum Therapy for disease... And trastuzumab in separate infusion bags, followed by vinorelbine worse cancer-related financial outcomes than men and 4.4210-8 ) Immunology... For metastatic disease S., Hughes, E., Wagner, S. L. Comparative of... Human breast cancer nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer gene datasets. May enhance the development of preventative therapies since 2019 Officer of Google Cloud since 2019,! Rs146023652, significantly associated with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) by.! Assistant professor joined the University of La Verne Legal Studies Department as an professor. I joined the University of La Verne Legal Studies Department as an assistant professor identified differentially expressed from! B., Taplin, S., Tshiaba, P., Rosenthal, E. Wagner. Of Science ID 000337925500007, in 2019, I joined the University of La Verne Studies! Modeling BRCA2-crisis invitro, we have derived insights into pre-neoplastic molecular alterations that may enhance the development of therapies... In separate infusion bags, followed by vinorelbine of La Verne Legal Studies Department as assistant!, P., Rosenthal, E., Wagner, S. L. Comparative effectiveness first-line! I joined the University of La Verne Legal Studies Department as an assistant professor nab-paclitaxel versus monotherapy. Derived insights into pre-neoplastic molecular alterations that may enhance the development of preventative therapies survival ( P=3.1910-8 and 4.4210-8..

Mahogany Okc Dessert Menu, Second Hand Stock Saddles For Sale Nz, Articles T